1. Home
  2. LGO vs BOLD Comparison

LGO vs BOLD Comparison

Compare LGO & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Largo Inc.

LGO

Largo Inc.

HOLD

Current Price

$0.46

Market Cap

71.3M

Sector

N/A

ML Signal

HOLD

Logo Boundless Bio Inc.

BOLD

Boundless Bio Inc.

BUY

Current Price

$2.58

Market Cap

60.8M

Sector

N/A

ML Signal

BUY

Company Overview

Basic Information
Metric
LGO
BOLD
Founded
1988
2018
Country
Canada
United States
Employees
N/A
N/A
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
71.3M
60.8M
IPO Year
2007
2024

Fundamental Metrics

Financial Performance
Metric
LGO
BOLD
Price
$0.46
$2.58
Analyst Decision
Buy
Analyst Count
2
0
Target Price
★ $2.20
N/A
AVG Volume (30 Days)
★ 1.0M
125.9K
Earning Date
11-11-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 32.47
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$42.04
N/A
Revenue Next Year
$14.74
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.44
$0.96
52 Week High
$2.70
$3.16

Technical Indicators

Market Signals
Indicator
LGO
BOLD
Relative Strength Index (RSI) 31.48 39.11
Support Level N/A $2.40
Resistance Level $0.83 $2.64
Average True Range (ATR) 0.05 0.13
MACD -0.02 -0.02
Stochastic Oscillator 6.91 25.49

Price Performance

Historical Comparison
LGO
BOLD

About LGO Largo Inc.

Largo Inc is committed to the production and supply of high-quality vanadium products. The company is also focused on the advancement of renewable energy storage solutions through Largo Clean Energy and its vanadium redox flow battery technology. The Company is engaged in the mining, exploration, and development of mineral properties, predominantly in Brazil, through which it produces and supplies vanadium products VPURE Flake, VPURE+ Flake, and VPURE+ Powder. The company has operating segments: sales & trading, mine properties, which generates key revenue, corporate, exploration and evaluation properties, Clean Energy, and Largo Physical Vanadium.

About BOLD Boundless Bio Inc.

Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.

Share on Social Networks: